S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

LLY Eli Lilly and Co

769.435

-4.41 (-0.57%)

Last Updated: 08:53:25

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Dec 2024 to Dec 2024

Click Here for more Eli Lilly Charts.

Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Eli Lilly Charts.

Eli Lilly and Co News

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Friday 20 December 2024 (2 weeks ago) • PR Newswire (US)

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Tuesday 17 December 2024 (2 weeks ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
Tuesday 17 December 2024 (2 weeks ago) • PR Newswire (US)

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
Friday 13 December 2024 (3 weeks ago) • PR Newswire (US)

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
Wednesday 11 December 2024 (3 weeks ago) • PR Newswire (US)

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
Monday 9 December 2024 (3 weeks ago) • PR Newswire (US)

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
Monday 9 December 2024 (3 weeks ago) • PR Newswire (US)

More Eli Lilly and Co News Articles

Irobot Corp Dl 01

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions